US 11,654,160 B2
Processes for making and using a mesenchymal stem cell derived secretome
Spencer Alford, Mountain View, CA (US)
Assigned to COMBANGIO, INC., Menlo Park, CA (US)
Filed by Combangio, Inc., Menlo Park, CA (US)
Filed on Apr. 7, 2020, as Appl. No. 16/842,696.
Application 16/842,696 is a continuation in part of application No. 16/785,463, filed on Feb. 7, 2020, granted, now 10,881,693.
Application 16/785,463 is a continuation in part of application No. 16/785,470, filed on Feb. 7, 2020, granted, now 10,758,571.
Claims priority of provisional application 62/929,035, filed on Oct. 31, 2019.
Claims priority of provisional application 62/831,371, filed on Apr. 9, 2019.
Prior Publication US 2021/0052656 A1, Feb. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61P 27/02 (2006.01); A61K 38/57 (2006.01); A61K 47/02 (2006.01); A61K 38/20 (2006.01); A61K 47/26 (2006.01); A61K 38/17 (2006.01); A61K 47/38 (2006.01); A61K 38/36 (2006.01); A61K 47/10 (2017.01); A61K 9/16 (2006.01); C07K 14/475 (2006.01); C07K 14/81 (2006.01); C12N 5/0775 (2010.01)
CPC A61K 35/28 (2013.01) [A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 38/177 (2013.01); A61K 38/1709 (2013.01); A61K 38/1833 (2013.01); A61K 38/1866 (2013.01); A61K 38/2053 (2013.01); A61K 38/36 (2013.01); A61K 38/57 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 27/02 (2018.01); C07K 14/475 (2013.01); C07K 14/8121 (2013.01); C12N 5/0663 (2013.01); C12N 5/0668 (2013.01)] 22 Claims
 
1. A method of treatment for an ocular condition in a subject in need thereof comprising administering to the subject a bone marrow-derived mesenchymal stem cell (MSC) secretome composition, wherein the MSC secretome composition comprises: HGF; Pentraxin-3 (TSG-14); VEGF; TIMP-1; Serpin E1; <5 ng/mL IL-8 and a tonicity modifying agent, and wherein the ocular condition is selected from the group consisting of: ocular wound, ocular scarring, ocular neovascularization, increased intraocular pressure, dry eye disease, damaged corneal surface, damaged ocular nerve tissue, retina condition, persistent corneal epithelial defects (PCED), Graft v. Host Disease (GvHD), and Stevens-Johnson Syndrome.